News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Biopharma desire to speed up the extraction and freezing process necessary for the safe transport of cell-based regenerative medicines is driving demand for cryopreservation reagents, according to biologics CDMOs.
The biosimilar market is expected to ramp up in Asia and Europe, even as it’s yet to be initiated in the US, with AbbVie, Amgen and Roche’s blockbuster biologics the most threatened, Moody's Investors Service says in a new report.
Big Biopharma has backed passage of Indiana substitution laws that require doctors to grant pharmacists permission to switch a biologic for a biosimilar.
Uptake in single-use is “off the charts” but there is still a growing market for traditional stainless steel technology, says Pall following its acquisition of ATMI.